Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prestige Consumer Healthcare (PBH) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Prestige Consumer Healthcare (PBH) over the last 17 years, with Q4 2025 value amounting to 16.96%.

  • Prestige Consumer Healthcare's EBITDA Margin rose 6300.0% to 16.96% in Q4 2025 from the same period last year, while for Dec 2025 it was 17.8%, marking a year-over-year decrease of 2900.0%. This contributed to the annual value of 18.58% for FY2025, which is 2400.0% up from last year.
  • As of Q4 2025, Prestige Consumer Healthcare's EBITDA Margin stood at 16.96%, which was up 6300.0% from 15.64% recorded in Q3 2025.
  • Over the past 5 years, Prestige Consumer Healthcare's EBITDA Margin peaked at 21.4% during Q4 2023, and registered a low of 84.87% during Q1 2023.
  • Its 5-year average for EBITDA Margin is 12.97%, with a median of 17.57% in 2025.
  • In the last 5 years, Prestige Consumer Healthcare's EBITDA Margin plummeted by -1059500bps in 2023 and then soared by 1005800bps in 2024.
  • Quarter analysis of 5 years shows Prestige Consumer Healthcare's EBITDA Margin stood at 18.74% in 2021, then increased by 14bps to 21.39% in 2022, then rose by 0bps to 21.4% in 2023, then fell by -24bps to 16.33% in 2024, then increased by 4bps to 16.96% in 2025.
  • Its EBITDA Margin stands at 16.96% for Q4 2025, versus 15.64% for Q3 2025 and 21.19% for Q2 2025.